Acute Respiratory Distress Syndrome Market: Epidemiology, Therapies, Companies, DelveInsight | Veru Inc., Direct Biologics, Athersys, Healios, MediciNova

Acute Respiratory Distress Syndrome therapies, such as Sabizabulin (Veru-111), ExoFlo (DB-001), and others, are expected to boost the Acute Respiratory Distress Syndrome Market in the upcoming years.

DelveInsight has launched a new report on "Acute Respiratory Distress Syndrome - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Acute Respiratory Distress Syndrome, historical and forecasted epidemiology as well as the Acute Respiratory Distress Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Acute Respiratory Distress Syndrome market report @ https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Acute Respiratory Distress Syndrome Market Report:

In 2023, the United States held the largest share of the Acute Respiratory Distress Syndrome (ARDS) market among the 7MM, valued at approximately USD 1,643 million.
The market is projected to grow further at a compound annual growth rate (CAGR) of 3.6%.
In 2023, the United States reported approximately 591,000 incident cases of Acute Respiratory Distress Syndrome (ARDS), representing the highest number among the seven major markets (7MM). The U.S. accounted for about 62% of the total ARDS incidence across the 7MM. In comparison, the combined regions of EU4 and the UK made up roughly 34% of the cases, while Japan contributed around 4% to the overall population share that year.
Current treatment approaches for ARDS primarily include neuromuscular blocking agents, inhaled vasodilators, corticosteroids, and other supportive therapies. Among these, inhaled vasodilators accounted for the largest market share, approximately USD 1,063 million, -in the 7MM in 2023.
In August 2024, MediciNova received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application concerning MN-166 (ibudilast) for the treatment of post-COVID conditions.
This growth is being driven by the increasing prevalence of respiratory illnesses, advancements in treatment options, and greater healthcare investment. Innovations in targeted biologics and advanced mechanical ventilation systems are also contributing to rising demand within the ARDS therapeutic space.
The overall ARDS market is expected to expand during the forecast period, fueled by the anticipated launch of new therapies such as Sabizabulin (VERU-111), ExoFlo, Invimestrocel, and Ibudilast.

In December 2024, PIF Partners announced that the FDA granted Rare Pediatric Disease Designation to its investigational therapy, 101-PGC-005 ('005), for managing flares of systemic juvenile idiopathic arthritis (sJIA). This agent, a Type IA prodrug of dexamethasone designed to specifically target CD206+ macrophages, is also being evaluated in a Phase 3 clinical trial in India for the treatment of COVID-19-induced acute respiratory distress syndrome (ARDS).
Key Acute Respiratory Distress Syndrome companies such as Veru Inc., Direct Biologics, Athersys, Healios, MediciNova, and others are evaluating new drugs for Acute Respiratory Distress Syndrome to improve the treatment landscape.
Promising Acute Respiratory Distress Syndrome therapies include Sabizabulin (Veru-111), ExoFlo (DB-001), and others.

Acute Respiratory Distress Syndrome Overview

Acute Respiratory Distress Syndrome (ARDS) is classified into three severity levels based on the PaO2/FiO2 ratio, a key parameter in guiding treatment:
Mild: 200-300 mmHg

Moderate: 100-200 mmHg

Severe: Less than 100 mmHg

ARDS can develop gradually over several days or progress rapidly. The earliest and most common symptom is shortness of breath, followed by signs such as low oxygen levels, rapid breathing, and abnormal lung sounds, including clicking, bubbling, or rattling, detected during auscultation.
Patients with ARDS often exhibit intense dyspnea, tachypnea, and hypoxemia, frequently accompanied by cough, fatigue, and generalized respiratory distress. The condition is commonly triggered by acute events like pneumonia, sepsis, trauma, aspiration of gastric contents, or exposure to toxic substances.
Several factors increase the risk of developing ARDS, including advanced age, chronic lung conditions, obesity, and immunosuppressed states, all of which can complicate both treatment and recovery.
Pathophysiologically, ARDS involves injury to the alveolar-capillary barrier, resulting in increased vascular permeability and fluid leakage into the alveoli. This leads to alveolar collapse (atelectasis), reduced lung compliance, and profound hypoxemia. The inflammatory response exacerbates lung injury, contributing to the syndrome's severity and complexity.

Acute Respiratory Distress Syndrome Market Outlook

Acute Respiratory Distress Syndrome (ARDS) is a severe, life-threatening condition initially identified as a form of respiratory failure resembling neonatal respiratory distress syndrome. It can be triggered by a range of pulmonary causes, such as pneumonia and aspiration, as well as non-pulmonary insults, including sepsis, pancreatitis, and trauma. These events lead to the development of non-cardiogenic pulmonary edema. ARDS is marked by an acute, widespread inflammatory injury in the lungs that increases alveolar-capillary membrane permeability, causes heavier lungs, and results in loss of functional lung tissue.

Clinically, ARDS presents as hypoxemia with bilateral opacities on chest X-rays. Patients often experience reduced lung compliance, increased venous admixture, and elevated physiological dead space. Histologically, the acute phase of ARDS is associated with diffuse alveolar damage.

Despite decades of investigation, treatment options for ARDS remain limited, with mechanical ventilation forming the cornerstone of supportive care. Other commonly used interventions include supplemental oxygen, prone positioning, neuromuscular blockade (paralytics), fluid management, and the application of Positive End-Expiratory Pressure (PEEP) to help displace fluid from the alveoli. These supportive measures are administered alongside treatment for the underlying cause.

Due to compromised immune function, ARDS patients are at heightened risk for secondary lung infections, such as bacterial pneumonia, for which antibiotics are typically administered. Additional supportive care, including intravenous fluids and nutritional support, may also be necessary.

A key pathological process in ARDS is alveolar flooding and pulmonary edema formation. Research has shown that β2-agonists can stimulate sodium transport in alveolar type I and II cells via β2-receptor activation, promoting faster clearance of pulmonary edema. Since epithelial damage plays a central role in ARDS, enhancing alveolar epithelial repair is crucial for recovery. Keratinocyte Growth Factor (KGF) has emerged as a promising agent in this regard, with both experimental and clinical studies suggesting its potential benefit in supporting lung repair in ARDS patients.

Discover how the Acute Respiratory Distress Syndrome market is rising in the coming years @ https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Acute Respiratory Distress Syndrome Emerging Drugs

Sabizabulin (Veru-111): Veru
ExoFlo (DB-001): Direct Biologics

Scope of the Acute Respiratory Distress Syndrome Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Acute Respiratory Distress Syndrome Companies: Veru Inc., Direct Biologics, Athersys, Healios, MediciNova, and others
Acute Respiratory Distress Syndrome Therapies: Sabizabulin (Veru-111), ExoFlo (DB-001), and others.
Acute Respiratory Distress Syndrome Therapeutic Assessment: Acute Respiratory Distress Syndrome current marketed and Acute Respiratory Distress Syndrome emerging therapies
Acute Respiratory Distress Syndrome Market Dynamics: Acute Respiratory Distress Syndrome market drivers and Acute Respiratory Distress Syndrome market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Acute Respiratory Distress Syndrome Unmet Needs, KOL's views, Analyst's views, Acute Respiratory Distress Syndrome Market Access and Reimbursement

To know what's more in our Acute Respiratory Distress Syndrome report, visit https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Acute Respiratory Distress Syndrome Market Report:
The Acute Respiratory Distress Syndrome market report covers a descriptive overview and comprehensive insight of the Acute Respiratory Distress Syndrome Epidemiology and Acute Respiratory Distress Syndrome market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Acute Respiratory Distress Syndrome market report provides insights into the current and emerging therapies.
The Acute Respiratory Distress Syndrome market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Acute Respiratory Distress Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Acute Respiratory Distress Syndrome market.

Got queries? Click here to know more about the Acute Respiratory Distress Syndrome market Landscape https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Acute Respiratory Distress Syndrome Patient Share (%) Overview at a Glance
5. Acute Respiratory Distress Syndrome Market Overview at a Glance
6. Acute Respiratory Distress Syndrome Disease Background and Overview
7. Acute Respiratory Distress Syndrome Epidemiology and Patient Population
8. Country-Specific Patient Population of Acute Respiratory Distress Syndrome
9. Acute Respiratory Distress Syndrome Current Treatment and Medical Practices
10. Unmet Needs
11. Acute Respiratory Distress Syndrome Emerging Therapies
12. Acute Respiratory Distress Syndrome Market Outlook
13. Country-Wise Acute Respiratory Distress Syndrome Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Acute Respiratory Distress Syndrome Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Acute Respiratory Distress Syndrome Market Outlook 2034 https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Acute Respiratory Distress Syndrome Pipeline Insights, DelveInsight

"Acute Respiratory Distress Syndrome Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Acute Respiratory Distress Syndrome market. A detailed picture of the Acute Respiratory Distress Syndrome pipeline landscape is provided, which includes the disease overview and Acute Respiratory Distress Syndrome treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.